:quality(90))
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer’sThe level of beta-amyloid removal by gantenerumab was lower than expected...| www.roche.com
As a pioneer in healthcare, we have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.| www.roche.com